Retlirafusp Alfa: First Approval
Author:
- 21 March 2026
- journal article
- other
- Published by Springer Nature in Drugs
- Vol. 86 (5) , 769-775
Abstract
Abstract Retlirafusp alfa (艾泽利®), a bifunctional antibody fusion protein combining a PD-L1-targeting antibody with a truncated form of the TGF-β receptor II (TGF-βRII) extracellular domain, is being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of solid malignant tumours. In January 2026, retlirafusp alfa was approved for use in combination with fluorouracil and platinum-based drugs as a first-line treatment for locally advanced, unresectable, recurrent, or metastatic gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEJA) with a PD-L1 positive CPS ≥ 1, as assessed by a well-validated assay in China. This article summarizes the milestones in the development of retlirafusp alfa leading to this first approval for the treatment of advanced PD-L1 positive GC/GEJA.This publication has 15 references indexed in Scilit:
- 298P SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ≥1: A post-hoc analysis of a phase III studyAnnals of Oncology, 2025
- LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)Annals of Oncology, 2024
- Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trialCancer Cell, 2024
- 511MO A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)Annals of Oncology, 2023
- 1026MO A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumorsAnnals of Oncology, 2023
- SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.Journal of Clinical Oncology, 2023
- SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I StudyClinical Cancer Research, 2022
- Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer ImmunotherapyBioDrugs, 2022
- Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancerCancer Communications, 2022
- Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatmentMolecular Oncology, 2021